Novo Nordisk hits back at copycat drugs
Gilts rebounded from earlier losses on Monday afternoon, and Novo Nordisk is suing US telehealth company Hims & Hers over ‘knock-off’ versions of its weight-loss drugs. Plus, France’s central bank chief is stepping down early, and US senators are pushing proposals to lift bank deposit insurance limits to avoid another…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like FT News Briefing →
Weight boss? Competition for Novo Nordisk
Novo Nordisk, Eli Lilly and the GLP-1 economy
Investing in weight-loss drugs, and why everyone’s talking about student loans
AI Labs: Sam Altman may make or break OpenAI
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.